Animal Drug GMP Inspections Now Under FDA-EU MRA Scope
May 31, 2023
The U.S.-EU Mutual Recognition Agreement (MRA) Sectoral Annex for Pharmaceutical Good Manufacturing Practices (GMP) has been expanded to include inspections of animal drugs. By utilizing each other’s inspection reports and related information, the MRA enables the FDA and the EU to avoid duplication of some animal drug inspections. READ MORE.

GADA in Support of Animal Drug User Fee Reauthorization
March 30, 2023
GADA Chair Stephanie Batliner testified in support of animal drug user fee reauthorization legislation before the Energy and Commerce Committee’s Health Subcommittee on March 30, 2023. Seated behind and to the right is Ben Moses, GADA Vice Chair. The legislation is critical to support efficient and predictable pathways to market for new and innovative animal drugs and generic animal drugs. GADA represents the generic animal drug industry in negotiations with the FDA Center for Veterinary Medicine.

Generic Animal Drug Advancement Act Introduced
March 21, 2023
The Generic Animal Drug Advancement Act, H.R. 1683, will update the Federal FD&C Act to correct current limitations to the approval of generic animal drug applications. “The Generic Animal Drug Advancement Act cuts bureaucratic red tape and ensures safe, effective, and affordable generic animal drugs are readily available. This will help farmers ranchers keep their livestock healthy and allow pet owners the best ability to take care of their pets. I'm so grateful to have such great partners in GADA and its members," said Rep. Mace. MORE

Wednesday, June 21, 2023
GADA Mid-Year Member Meeting

Thursday, June 22, 2023
GADA-CVM Triannual Meetings

Wednesday, October 25, 2023
GADA Annual Member Meeting

Thursday, October 26, 2023
GADA-CVM Triannual Meetings